My Treatment Approach: Improving Chronic Lymphocytic Leukemia Management and Treatment Outcomes - Episode 11

Navigating 2L Treatment Options in CLL

July 30, 2024

Catherine C. Coombs, MD, Bita Fakhri, MD, MPH, John N. Allan, MD

Experts on chronic lymphocytic leukemia discuss treatment practices for patients with relapsed/refractory CLL and provide insights on the role for venetoclax in patients who previously received BTK inhibitors.

Video Player is loading.

Current Time 0:00

Duration 5:53

Loaded: 0%

Stream Type LIVE

Remaining Time 5:53

EP. 1: Patient with Newly Diagnosed CLL with High-Risk Features

EP. 2: Expert Perspectives on 1L Treatment Approaches in Newly Diagnosed CLL

EP. 3: Navigating Continuous BTKi Therapy for CLL in the 1L Setting

EP. 4: Implications of Real-World Data in the 1L Treatment of High-Risk CLL

EP. 5: Expert Perspectives on Venetoclax-Based 1L Treatment Strategies in CLL

EP. 6: Considerations for 1L Doublet and Triplet Therapy with Venetoclax in CLL

EP. 7: Perspectives on Shared Decision-Making in the Treatment of CLL

EP. 8: Strategies for Optimizing Venetoclax-Based Treatment for Patients with CLL

EP. 9: Expert Insights for Long-Term Treatment Planning in CLL

EP. 10: Patient with R/R CLL Treated with 2L Venetoclax Therapy

Now Viewing

EP. 11: Navigating 2L Treatment Options in CLL

EP. 12: Emerging Data with BTKi Resistance: Expert Insights and Treatment Implications

EP. 13: Management Strategies for BTKi-Related CVAEs in CLL

EP. 14: Updates in CLL Treatment Strategies with Noncovalent BTKis

EP. 15: Looking Ahead: Novel Therapies and Future Perspectives in the Treatment of CLL

Video content above is prompted by the following questions:

What is your general treatment approach in patients with R/R CLL?
- How does prior 1L therapy influence your treatment decision?
- How does your approach to 2L treatment differ from 3L+?
- In what clinical scenarios may you consider venetoclax for patients with R/R CLL?